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Objective: We retrospectively evaluated long-term oncological outcomes in patients with
germ cell tumors (GCTs) primarily treated at our institution and assessed late recurrence and
second primary malignancies.
Methods: This study included a total of 139 males with newly diagnosed GCTs of the testis
or extragonadal origin who received treatment, including surgery, chemotherapy and radiation
therapy, at our hospital between 1980 and 2005. We reviewed late recurrence that occurred
at least 2 years after the initial disease-free status and secondary malignancies as well as
oncological outcomes.
Results: In patients with seminoma, 5-year progression-free survival and cause-speciﬁc sur-
vival rates were 87.2% and 100% for Stage I, 88.9% and 100% for Stage II, and 50.0% and
50.0% for Stage III, respectively, whereas in those with non-seminomatous GCTs, they were
79.1% and 96.3% for Stage I, 89.5% and 89.4% for Stage II, and 85.7% and 78.4% for
Stage III, respectively. Late recurrence was found in ﬁve (3.6%) patients and all of them
responded to salvage treatment and achieved disease-free status. Second primary hemato-
logical neoplasms occurred in three (2.2%), although they had a long-term free of the primary
disease. All died of the second primary disease.
Conclusions: Late recurrence was successfully managed with appropriate treatments, although
its incidence was not negligible. Periodic follow-up may be necessary for .5 years in patients
with GCTs for early detection of late recurrence. In addition, care should be taken to watch for the
development of life-threatening second primary malignant disease during long-term follow-up.
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INTRODUCTION
Germ cell tumors (GCTs), mainly presenting as testicular
cancer, are relatively rare neoplasms that account for 0.8%
of all cancers in males (1). However, GCTs are the most
common malignancy among men aged 15–44 years old (2).
GCTs have been considered to be curable malignancies,
even in the advanced stage, since the introduction of cispla-
tin (3). Because GCTs occur in young patients, improvement
of the prognosis has caused a new clinical problem. Disease
recurrence is often found after even more than 5 years (4),
and there is no consensus on how long we should follow up
patients with periodic examinations. The occurrence of a
second primary malignancy is also clinically signiﬁcant,
because chemotherapy and radiotherapy may increase the
risk for such an onset after a long-term duration (5). Little is
known about second malignant neoplasms in Japanese men
who become free of testicular cancer. This is partly because
Japanese men have a much lower incidence of the disease
than Caucasian men (6), and thus each institute has a limited
number of patients.
In this study, we reviewed long-term oncological out-
comes in patients with GCT receiving treatment at our
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second malignant neoplasms.
PATIENTS AND METHODS
This retrospective study included 139 males with newly
diagnosed GCTs of the testis or extragonadal origin treated
at our hospital between 1980 and 2005. These patients
underwent single or combined treatments including surgery,
radiation and chemotherapy according to the extent of the
disease. All patients were diagnosed by histological examin-
ation of the primary or metastatic site, except for one patient
with a disease of mediastinal origin, in whom non-
seminomatous GCT (NSGCT) was presumed to be due to
elevated serum a-fetoprotein and human choriogonadotropin.
Clinical stage was determined based on the 1997 version of
the UICC tumor stage classiﬁcation (7). All of the patients
with metastatic disease received platinum-agent-based che-
motherapy and, if indicated, subsequent surgical resection of
the residual mass. The exception was patients with pure
seminoma having a solitary metastatic mass in an abdominal
lymph node ,5 cm in diameter who underwent radiation
therapy or chemotherapy for the metastasis. Selected patients
with organ-conﬁned disease in the early 1980s received pro-
phylactic treatment such as chemotherapy, retroperitoneal
lymph node dissection (RPLND) or radiation therapy.
Although follow-up intervals depended on the stage of the
disease, the evaluation was basically done as follows. In the
ﬁrst 2 years, the follow-up consisted of measurement of
tumor markers such as AFP, HCG, and HCG-b every 1–2
months. A complete blood count, blood chemistry and com-
puted tomography (CT) of lung and abdomen were done
every 3 months. In the next 3–5 years, tumor markers, com-
plete blood counts and blood chemistry were evaluated every
3–6 months. CT was done every 3–12 months, depending
on the stage of the disease and follow-up period. After 6–10
years, we followed patients semi-annually or annually with
tumor markers, complete blood counts and blood chemistry
evaluations. CT was done if clinically indicated. After 10
years, patients were followed up annually with the clinical
examinations described above if needed.
Late recurrence and the occurrence of second malignancy
were reviewed. The recurrence was deﬁned as that with an
initial histological diagnosis of testicular or extragonadal
GCT and recurrence of disease .2 years after the initial suc-
cessful treatment. Metachronous GCTs that arose from the
contralateral testis were excluded from late recurrence.
Progression-free survival (PFS) and cause-speciﬁc survival
(CSS) were estimated by the Kaplan–Meier method.
RESULTS
The patients’ characteristics are shown in Table 1. The mean
age was 32.5 years and they were followed up for a median
period of nearly 6 years. The median follow-up period of
current survivors was 7.4 years, with a mean period of 8.6
years. Extragonadal GCTs were found in four patients, three
with retroperitoneal disease and one with a mediastinal one.
Histological examination revealed pure seminoma in 38.1%
of the patients and tumors including a non-seminomatous
component in 61.9%. For metastatic lesions, 2 patients
received radiation therapy alone and 66 had chemotherapy
Table 1. Patients’ characteristics
No. of patients 139
Mean age: years (range) 32.5 (15–56)
Median follow-up period: months (range) 75.5 (2.4–304)
Primary site (n)
Testis (right/left) 135 (68/67)
(97.1%)
Retroperitoneal 3 (2.2%)
Mediastinum 1 (0.7%)
Histology (n)
Seminoma 53 (38.1%)
Clinical stage
I4 1
II 9
III 3
Non-seminomatous germ cell tumor 86 (61.9%)
Clinical stage
I3 0
II 20
III 36
Treatment added to orchiectomy (n)
None 25
Radiation only 38
Chemotherapy only 16
Radiation þ chemotherapy 2
Chemotherapy þ surgical resection of metastatic
site
54
RPLND only 4
Chemotherapy regimen (n)
PVB 27
BEP/EP 63
VIP 19
VeIP 2
High-dose ICE þ autologous HCT 11
TIP/TIN 6
Irinotecan þ nedaplatin 5
RPLND, retroperitoneal lymph node dissection; PVB, cisplatin þ
vinblastine þ bleomycin; BEP, bleomycin þ etoposide þ cisplatin; VIP,
etoposide þ ifosphamide þ cisplatin; VeIP, vinblastine þ ifosphamide þ
cisplatin; ICE, ifosphamide þ carboplatin þ etoposide; HCT, hematopoietic
cell transplantation; TIP, paclitaxel þ ifosphamide þ cisplatin; TIN,
paclitaxel þ ifosphamide þ nedaplatin.
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motherapy were given to three patients. As the ﬁrst-line
regimen, PVB (cisplatin þ vinblastine þ bleomycin) was
used from 1980 to 1990, whereas BEP (bleomycin þ
etoposide þ cisplatin) was used after 1990.
In the early 1980s, some patients received combination
chemotherapy with cisplatin, vinblastine, peplomycin and
adriamycin as the ﬁrst-line treatment. Various chemothera-
peutic regimens were used as the second- or third-line treat-
ment as shown in Table 1. A combination of paclitaxel and
irinotecan was introduced in 2003. Details of management
for advanced disease will be reported elsewhere.
Disease-free status was achieved in 92.1% of the patients
by the initially planned treatment. Of them, however, 12.2%
developed recurrent disease and a GCT appeared in the con-
tralateral testis in 1.4%. On the other hand, 11 (7.9%)
patients never became free from the disease. Finally, 11
(7.9%) patients died of the primary disease. Four patients
died of chemotherapy-related complications. Life-threatening
second malignant disease developed in three patients who
had undergone chemotherapy for GCTs (Table 2). Details of
their clinical courses are discussed below.
Figure 1 presents the PFS of patients with seminoma
and that of those with NSGCTs. One patient with seminoma
and 9 with NSGCTs were never free of the disease after
the initially planned treatments and all of these 10 were
excluded from the analysis of PFS. Stage I disease had worse
5- and 10-year PFS than Stage II disease due to the difference
in the recurrence rate. However, CSS was excellent in Stage I
disease for both types of histology (Fig. 2).
Late recurrence was seen in ﬁve patients (3.6%), including
three with Stage I NSGCT, one with Stage I seminoma and
one with Stage III NSGCT (Table 3). Interestingly, one
patient with Stage I NSGCT developed abdominal lymph
node metastasis 7 years after the primary tumor resection.
Treatments consisting of chemotherapy and mass resection
were successful for the recurrent disease in all patients.
Patients who developed a second primary malignant
disease after the treatment for GCTs are shown in Table 4.
They received chemotherapy before 1985. In three patients
who developed hematologic neoplasms, two had seminoma
in the primary lesion and had undergone prophylactic or
therapeutic radiation therapy. All three patients had a history
of chemotherapy with a regimen containing cisplatin for the
original and recurrent disease, whereas etoposide was admi-
nistered to one patient. There was another patient who devel-
oped renal cell carcinoma (RCC) 20 years after the initial
treatment for testicular cancer. He received orchiectomy and
RPLND for Stage I disease. After the initial treatment, lung
metastasis was found 1.5 years later. He received combi-
nation chemotherapy consisting of cisplatin, vinblastine,
peplomycin and adriamycin. He underwent a nephrectomy
for RCC and is now the only survivor among those who had
a second primary malignancy.
DISCUSSION
In this study, we reviewed the outcomes of patients with
GCTs since the introduction of cisplatin. Multimodal treat-
ments consisting of surgical resection, radiation and
Table 2. Outcome of patients
Total no. 139
Disease-free after the initially planned treatment 128 (92.1%)
Disease recurrence 17 (12.2%)
Median time to recurrence: months (range) 8 (1.1–84)
Metachronous appearance in contralateral testis 2 (1.4%)
Disease remaining after the initially planned treatment 11 (7.9%)
Alive without disease 117 (84.2%)
Alive with disease 3 (2.2%)
Died of the primary disease 11 (7.9%)
Died of chemotherapy-related complications 4 (2.9%)
Died of second malignant disease 3 (2.2%)
Died of disease other than germ cell tumor 4 (2.9%)
Figure 1. (A) Progression-free survival (PFS) of 52 patients with semi-
noma. (B) PFS of 77 patients with non-seminomatous germ cell tumors
(NSGCTs).
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patients with clinical stage I and II diseases, as other investi-
gators reported (8). However, the result of treatment for the
systemic disseminated disease is still unsatisfactory (9),
although details of our results were not fully reported in this
manuscript. Only a few years have passed since the newer
anti-cancer agents such as paclitaxel and irinotecan began to
be employed. Therefore, further observation is needed to
evaluate the long-term efﬁcacy of these drugs.
The incidence of late recurrence was 3.6%, which was
similar to those in other reports (10). Most patients who
developed late recurrence had Stage I disease with surveil-
lance after tumor resection, and relapse .5y e a r sa f t e rt h e
diagnosis of GCT may be rare in patients with advanced
disease who receive chemotherapy and become free of the
disease. These results suggest the efﬁcacy of adjuvant che-
motherapy to prevent disease recurrence in some patients
with Stage I disease. However, the use of chemotherapeutic
agents entails a risk of de novo primary malignancy, as dis-
cussed below (11). In addition, all of our patients with late
recurrence successfully obtained freedom from disease by
chemotherapy with residual mass resection. Taking these
ﬁndings and the incidence of late recurrence into consider-
ation, adjuvant chemotherapy may not always be necessary
for Stage I GCT patients, except those with a high risk for
disease recurrence (12), as long as they receive close
follow-up (13,14). Oldenburg et al. (15) reported that
RPLND might be effective to prevent late relapse in Stage I
GCT. However, because of its invasiveness and low inci-
dence of relapse, it is controversial whether RPLND should
be performed. Similar to adjuvant chemotherapy, if close
follow-up can be done, immediate RPLND may not be
necessary in Stage I disease.
Some anti-cancer agents have potential oncogenicity.
Topoisomerase II inhibitors increase the risk for secondary
leukemia arising in 2 or 3 years (16), with a relative risk of
15–25% (5). However, our leukemic patient had not been
administrated etoposide. Moreover, the onset was too late for
topoisomerase II-speciﬁc leukemia. Travis et al. (17)
reported that both radiation therapy and chemotherapy pro-
moted the risk for leukemia in long-term survivors. Even in
our cases, the combined therapy might affect the develop-
ment of leukemia after a long duration. On the other hand,
alkylating agent-related myelodysplastic syndrome and acute
myeloid leukemia often occur 5–7 years after the adminis-
tration (18). Our two cases presented its typical course. In
this study, one patient developed secondary solid organ
Table 3. Patients with late recurrence after initial treatment
Stage Histology Initial treatment added to
radical orchiectomy
Time to
relapse
(months)
Site of
relapse
Tumor markers at
relapse (AFP/
HCG-b)
Outcome Period after the treatment
for recurrent disease
(months)
IE þ T þ S None 26 RPLN, lung 24.9/1.5 NED 65
I S None 46 Dura mater 1.2/0.1 NED 105
IT þ S None 84 RPLN 465/0.2 NED 5
IE þ T RPLND 25 RPLN 69.0/5.0 NED 196
IIIB2 E þ Y þ C þ T Chemotherapy þ tumor
resection
59 Mediastinum 1085/69.0 NED 115
AFP, a-fetoprotein; HCG-b, human chorionic gonadotropin-b subunit; E, embryonal carcinoma; T, teratoma; S, seminoma; RPLN, retroperitoneal lymph
nodes; NED, no evidence of disease; Y, yolk sac tumor; C, choriocarcinoma. HCG was not examined at the time of relapse in these cases.
Figure 2. (A) Cause-speciﬁc survival (CSS) of 53 patients with seminoma.
(B) CSS of 86 patients with NSGCTs.
160 Late recurrence, second malignancy, germ cell tumormalignancy. Its frequency was extremely rare, although if
the follow-up period were to be prolonged, solid organ
malignancy might increase. Treatment-related solid organ
cancers have developed 20 years after radiation therapy and
chemotherapy (19). Thus, further follow-up might detect
secondary solid organ malignancies in our series.
There is no consensus on the duration of periodic follow-up
for GCT patients. As shown in this study, some patients prob-
ably develop relapse of the disease .5 years after the initial
diagnosis (20). We successfully detected and managed all
patients with late relapse in the follow-up periods. Patients who
are diagnosed as having a late recurrence after presentation of
the recurrence-related symptoms have a tendency to have
poorer prognoses (21,22). When we take this into consider-
ation, follow-up for at least 10 years may be preferable (15).
Since long-term survivors who undergo chemotherapy
and/or radiation therapy have a high risk for second malig-
nancy, we should carefully follow them to detect the disease.
Follow-up .10 years may be needed. However, periodical
examinations cannot always detect a second malignant
disease. In addition, the clinical efﬁcacy of early detection
of second malignancy is still unknown, because the disease
tends to be refractory to treatment. Further investigation is
needed to establish the management procedure for a second
malignant disease.
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